ARTICLE | Clinical News

Axokine: Phase II

December 4, 2000 8:00 AM UTC

In a 12-week U.S. Phase II dose ranging trial of 170 severely or morbidly obese patients, self-administered subcutaneous injections of 1 ug/kg or 2 ug/kg of Axokine gave significant weight loss (the primary end point) compared to placebo in all patients and in patients that completed the study (p<0.0001 for both analyses). Patients receiving the optimal Axokine dose (1 ug/kg) lost an average of 10 pounds more than patients on placebo (p<0.0001), and 46 percent of those patients lost at least 10 pounds, compared to 5 percent of patients on placebo. In a group of patients who received 1 ug/kg of Axokine for 8 weeks followed by 4 weeks of placebo, lost weight was not regained while on placebo. ...